Multiplexed Fluorescence Assay for Antibody Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for assessing the specificity and tissue cross reactivity of antibodies or antigen binding fragments are laborious, time-consuming, and prone to high inter-observer variability, limiting their effectiveness in ensuring drug safety, particularly in CAR immune cell therapy.
Innovation Solution
A multiplexing approach that involves contacting antigen recognizing moieties conjugated with fluorescent moieties with tissue samples, allowing for the comparison of binding specificity and tissue cross reactivity by analyzing the intensity and spatial distribution of fluorescence signals, thereby identifying suitable binders for targeted therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional immunohistochemistry is used for tissue cross reactivity studies, then binding specificity can be assessed, but the method is laborious and time consuming
Solution Approach 1:
The patent combines multiple immunohistochemistry staining procedures into a single multiplexed assay. Multiple antigen recognizing moieties are simultaneously detected in the same tissue section using different fluorescent labels, allowing comprehensive cross-reactivity assessment in one experiment rather than sequential single-marker staining.
Solution Approach 2:
The method creates a universal platform for assessing multiple binders across multiple tissue types simultaneously. The tissue microarray format with multiplexed detection allows a single assay to evaluate cross-reactivity profiles of multiple candidate antibodies against numerous tissue targets, making the system highly versatile for preclinical safety assessment.
2Measurement precision
If conventional immunohistochemistry is used for tissue cross reactivity studies, then binding specificity can be assessed, but inter-observer variability is high
Solution Approach 1:
The patent incorporates automated image analysis with objective quantification algorithms that process fluorescent signal patterns. The system compares staining patterns of test antibodies against reference antibodies with known specificity, providing standardized, algorithm-driven assessment that eliminates subjective interpretation and reduces inter-observer variability.
Solution Approach 2:
The method replaces manual visual assessment by pathologists with automated computational image analysis. Digital imaging systems capture fluorescent signals, and software algorithms objectively quantify staining patterns, replacing the mechanical/subjective human observation process with an automated, reproducible digital system.
3Device complexity
If only one marker per tissue section is used, then simple analysis is possible, but multiplexing capability is limited
Solution Approach 1:
The patent adds the dimension of spectral multiplexing by using multiple fluorescent labels with distinct emission wavelengths. Instead of analyzing one marker at a time, the system simultaneously detects multiple antibodies labeled with different fluorophores (e.g., FITC, TRITC, Alexa dyes) along the spectral dimension, enabling parallel assessment of multiple binders.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables efficient assessment of the specificity and tissue cross reactivity of novel binders, facilitating the selection of antigen recognizing moieties with high target specificity and minimal off-target reactivity, thereby improving the safety and efficacy of immune cell therapies.
Implementation Method 1
conjugates with antigen recognizing moieties that have been contacted with units such as tissues on an aggregate such as a tissue microarray, wherein every binder comprises a conjugate comprising a fluorescent moiety and an antigen recognizing moiety
Data Source
AI summary
The present invention provides an in-vitro method that allows to assess specificity as well as tissue cross reactivity of novel binders. i.e. antigen recognizing moieties such as antibodies or antigen binding fragments thereof, wherein said binders may be beneficially used in e.g. CAR T cell therapy.